Protocol Ledger

NCT05003245 · Phase III · COMPLETED

Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

Interventional Phase III clinical trial protocol NCT05003245 sponsored by Shanghai Henlius Biotech in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-01 Enrollment: 407 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05003245
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)407 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05003245
Protocol FieldVerified Registry Value
NCT IdentifierNCT05003245
Consolidated Lead SponsorShanghai Henlius Biotech
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment407 participants (ACTUAL)
Registered Start Date2021-11-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI